TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03495011

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast MRI
Description: Quantitative, multiparametric breast MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Breast MRI
Description: Quantitative, multiparametric breast MRI

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Only patients with pure DCIS on surgical excision will have advanced pathologic markers and Oncotype Dx DCIS Score testing.
Study: NCT02548767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fructose corn syrup
Description: High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fructose corn syrup
Description: High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aspartame
Description: Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aspartame
Description: Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy-balanced diet
Description: Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-balanced diet
Description: Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad libitum diet
Description: Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum diet
Description: Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Study: NCT06579729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention for low free sugars
Description: After baseline data collection, the intervention group received a 30-60 minute educational session with a dietitian and clinicians, including a health education prescription. Interventions occurred at weeks 1, 12 and 24, with routine evaluations of disease, diet, physical activity, and adherence. Follow-ups at 48 weeks assessed NAFLD extent, dietary profile, and health knowledge for both subjects and guardians.
Study: NCT04109391

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin (trastuzumab)
Description: Subjects will receive up to 13 cycles of adjuvant treatment.
Study: NCT00945035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: etoricoxib
Description: Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
Study: NCT03617614

Intervention type: BEHAVIORAL
Intervention: Collaborative Care Model
Description: Trained care managers (CM) work collaboratively with patients, caregivers, and primary care providers to provide education, care navigation and behavioral activation. The latter includes a stepped psychotherapy intervention called ENGAGE, that focuses on reward exposure engagement in meaningful, rewarding activities for patients. Patients (home) visits are delivered over a period of 6 to 16 weeks. Progress is assessed with standardized measures for depression (PHQ-9), anxiety (GAD-7) and functioning (WHO-DAS). Furthermore, patients are presented by the CM at Systematic Case Review meetings where an integrated team of medical, psychiatric and allied health professionals work collaboratively to review the patient's goals and treatment to formulate a care plan and recommendations.

Intervention type: BEHAVIORAL
Intervention: Mood Consultation
Description: A meeting with a psychiatrist to do assessment, provide education and make recommendations regarding the care of the patient for the Primary Care Provider.
Study: NCT00280397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7080
Description: E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
Study: NCT02310529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.~Intervention will be delivered by trained clinical psychologists.
Study: NCT01872533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia Exposure
Description: Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at \~ 15% O2 (ca. 2400 m elevation).
Study: NCT03054155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alexandrite Laser
Description: Alexandrite 755nm hair removal laser
Study: NCT04213066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable tablet
Description: Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
Study: NCT04334473

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification and Intraocular lens implantation
Description: Standartd surgical procedure with small incision to remove catarct using ultrasound waves. it can be done by topica, local or general anaesthesia acoording to patients general fitness and preference.
Study: NCT04213066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable tablet
Description: Each training session was limited to 15 minutes a day, 5 days a week. The entire training period was 6 months.
Study: NCT04334473

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound Biomicrosopy (UBM)
Description: A diagnostic test using ultrasound waves to evaluate the anterior chamber depth, angle and lens vault.
Study: NCT04275700

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-PRP
Description: The cortex of each ovary will be injected with autologous platelet rich plasma. Up to seven different sites will be injected under ultrasound guidance. The patient will be under IV sedation.
Study: NCT02221167

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Donor Milk
Description: breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in.
Study: NCT04220164

Intervention type: OTHER
Intervention: Education and inform the optimal threshold of LDL-C levels
Description: Physicians educate patients and provide a clear information about optimal LDL-C value according to individual patient's condition according to current guidelines
Study: NCT03016767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual oral stimulation protocol
Study: NCT03319537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pevonedistat
Description: Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pevonedistat
Description: Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed and cisplatin
Description: Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
Study: NCT01572779

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BSM device with bio-feedback
Description: A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BSM device with no bio-feedback
Description: The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
Study: NCT00530127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Same dose and frequency as treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone
Description: 100 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone
Description: 100 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Same dosage and frequency as study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferiprone
Description: 100 mg/mL
Study: NCT00857896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine
Description: 4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
Study: NCT03854825

Intervention type: PROCEDURE
Intervention: Cardiac surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Study: NCT03756623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin powder
Description: 0.5g of Metformin powder administered three times a day orally before meal
Study: NCT02428322

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VItamin D3
Description: Soft gel capsules will contain 2,000IU vitamin D.
Study: NCT02964416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Tramadol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% Normal saline in 10 ml syringe
Study: NCT01578148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Noxipoint Therapy
Description: Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:~1. Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).~2. Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.~3. Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.~4. Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:~1. TENS stimulation (45 minutes):~   • Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.~2. Other modalities of PT per the therapist's choice:~   * Infrared treatment on the pain areas (about 15 minutes)~  * Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).~  * Exercise and training:~     * Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or~    * Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes~  * Hot/cold pack to the pain area for about 15 minutes
Study: NCT03883815

Intervention type: OTHER
Intervention: Active Video Games Therapy
Description: Interventions were completed in 1-week periods, after 3 clinical visits. All individuals underwent both neurodevelopmental therapy and active video games therapy. Demographic data of individuals were recorded and muscle tone and gross motor functions were evaluated at the first visit. The games determined by the physiotherapist were explained and experienced by individuals. During the second visit, individuals played 4 games that were previously determined and experienced for about 45 minutes. On the last visit, individuals underwent neurodevelopmental therapy. During both treatment sessions, the accelerometer was fitted on a flexible belt by attaching it to the dominant wrist. Individuals were instructed not to remove the device during both treatment sessions.~One session individuals treated with exercises which weight transfer and postural reactions were facilitated.~Other session they played Nintendo Wii games in accordance with their current level and skills.
Study: NCT02255357

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing only the excipients of the original solution without Oxytocin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
Study: NCT03756623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics powder
Description: 0.5g of Probiotics powder administered three times a day orally before meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: 0.5g of Placebo powder administered three times a day orally before meal
Study: NCT03804450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedures (REPs)
Description: Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative endodontic procedures (REPs)
Description: Instrumentation using rotary Pro-Taper Next, disinfection using sodium hypochlorite and calcium hydroxide as intracanal medication followed by induction of blood and application of Biodentine as a cervical plug.
Study: NCT00708812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar(Recombinant Human Endostatin Injection)
Description: Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-carboplatin
Description: paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel-carboplatin
Description: paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
Study: NCT04180514

Intervention type: DIAGNOSTIC_TEST
Intervention: intradialytic hypotension episode
Description: Intradialytic hypotension episode under regular hemodialysis
Study: NCT03806725

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravenous administration of iodinated contrast medium for coronary CT angiography
Description: Administration of iodinated contrast medium for coronary CT angiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Intravenous administration of iodinated contrast medium for coronary CT angiography
Description: Administration of iodinated contrast medium for coronary CT angiography
Study: NCT03107585

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral cervical plexus block
Description: with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: bilateral cervical plexus block
Description: with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
Study: NCT02308891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lactated Ringer's solution (vigorous hydration arm)
Description: * Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP~* Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.~* At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactated Ringer's solution (standard hydration arm)
Description: - Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic retrograde cholangiopancreatography (ERCP)
Description: endoscopic retrograde cholangiopancreatography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscopic retrograde cholangiopancreatography (ERCP)
Description: endoscopic retrograde cholangiopancreatography
Study: NCT00763958

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match buprenorphine administered for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
Study: NCT04512196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Superoxidized Water
Description: Super-oxidized solution contains hypochlorous acid (HOCl) which exhibits bactericidal activity. These reactive species create an imbalanced osmotic gradient which damages the cell membrane integrity of single celled organisms, and subsequently denaturing its lipid and protein content. Multicellular organisms including host tissue are not susceptible to such changes in osmolarity hence spared from damage.
Study: NCT02891720

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proteus Sensor System
Description: The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
Study: NCT02695355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Description: Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
Study: NCT01535820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
Description: NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
Study: NCT04512196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline contains 0.9% sodium chloride.